Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | FABP7 | O15540 | 2/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | TLR2 | O60603 | 1/20 | 0.33 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | MDM4 | O15151 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.31 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23156981 | 1.00 | KMT2A (0.44) | KMT2AFABP7FABP5MEN1OPRD1 | |
| SCHEMBL25658800 | 1.00 | KMT2A (0.44) | KMT2AFABP7FABP5MEN1OPRD1 | |
| SCHEMBL25658818 | 1.00 | KMT2A (0.44) | KMT2AFABP7FABP5MEN1OPRD1 | |
| SCHEMBL25846320 | 0.93 | KMT2A (0.41) | KMT2AFABP7FABP5OPRD1FFAR2 | |
| SCHEMBL24579138 | 0.93 | KMT2A (0.39) | KMT2AFABP7FABP5OPRD1FFAR2 | |
| SCHEMBL26045350 | 0.91 | KMT2A (0.39) | KMT2AFABP7FABP5MEN1OPRD1 | |
| SCHEMBL25846454 | 0.91 | KMT2A (0.39) | KMT2AFABP7FABP5MEN1OPRD1 | |
| SCHEMBL28773147 | 0.90 | KMT2A (0.53) | KMT2AFABP7FABP5OPRD1EPHX2 | |
| SCHEMBL25657687 | 0.87 | KMT2A (0.48) | KMT2AFABP7FABP5EPHX2MDM4 | |
| SCHEMBL23056431 | 0.85 | CASP3 (0.38) | FABP7FABP5FFAR2KIF11MDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | KMT2A 3145/4885FABP7 4602/4885FABP5 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.